BCTG Acquisition Corp.
Status: Deal Closed
U=S
| IPO Proceeds, $M | $166.75M |
|---|---|
| IPO Date | Sep 3, 2020 |
| CEO | Aaron I. Davis |
| Left Lead | SVB Securities |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology in North America and Europe |
| IPO Geography | Global |
| Target Company | Tango Therapeutics |
| Deal Announced | Apr 14, 2021 |
| Deal Size, $M | $352.75M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Aug 9, 2021 |
| Amendment Vote | TBD |
| Closing Date | Aug 10, 2021 |
Formerly BCTG
TNGX
| Price | $4.08 |
|---|---|
| Last closing price | $3.85 |
| H/L, today | $3.71 / $4.09 |
| H/L, 52-week | $2.47 / $13.03 |
| Volume, today | 2,499,081 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on BCTG Acquisition Corp.:
- Structure and cap table
- 9 directors & officers
- 17 filings and events
- 1 underwriters
- 7 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Aaron I. Davis | 42 | Chairman and CEO |
| Christopher Fuglesang, Ph.D., J.D. | 52 | President and Director |
| Michael Beauchamp | 30 | CFO and Treasurer |
| Andrew Ellis, M.D., J.D. | 37 | Director |
| Carole L. Neuchterlein, J.D. | 59 | Director |
| Richard Heyman, Ph.D. | 62 | Director |
| Charles M. Baum, M.D., Ph.D. | 62 | Director |
| Jamie G. Christensen, Ph.D. | 52 | Director |
| James B. Avery | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| SVB Securities | BR | 14,500,000 | units |
| 14,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.